TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Greene Climacteric Scale score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Area Under the Serum Concentration-Time Profile From Time 0 Extrapolated to Infinite Time (AUCinf)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Serum Concentration-Time Profile From Time 0 to the Time of the Last Quantifiable Concentration (AUClast)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in disease-specific functional outcome
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Overall Response Rate (ORR) at 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual attention - dwell time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual attention - time to first fixation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in behavioral intentions
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Epileptiform activity at EEG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Changes in Headache impact test (HIT-6)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Changes in Migraine disability assessment test (MIDAS)
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Hemostatic success within 3 minutes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Heel rise test for endurance and maximal height
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: General Cognitive function
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in number of FMF attacks per month
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concentration of interleukin-10
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Neurological and cognitive disorders
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Usability of video-interpreting
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Impact on emergency physician's decisions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Energy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in fasting blood tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: changes in Tg level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Continuous contraceptive use
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Maximum Observed Plasma Concentration (Cmax) of Vepdegestrant
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf) of Vepdegestrant
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical Activity (Response)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Atherosclerosis in CCTA Arm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of Subjects Eligible for Treatment Based on Automated Plaque Assessment from CCTA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: information access
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in number of participants with successful linkage to recovery resource
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Diagnostic accuracy to detect advanced fibrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic performance to increase correct referrals
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic performance to decrease incorrect referrals
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Healthfulness of product selection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Carbon footprint of participants' grocery store selections
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Time to Aldrete score > 9
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time from end of operation to PACU
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sore Throat Visual Analogue Scale (VAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EuroQol 5 Dimension Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Glaucoma medication use
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Interpersonal Reactivity Index - IRI
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Multifaceted Empathy Test - MET
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Kliniske Undersøgelser Side Effect Rating Scale - UKU-SERS
Endpoint domain: Adverse events/effects
Primary endpoint: Maslach's Burnout Inventory - MBI
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Incidence of serious drug-drug interactions
Endpoint domain: Adverse events/effects
Primary endpoint: Median number of serious drug-drug interactions
Endpoint domain: Adverse events/effects
Primary endpoint: Complete remission (CR) and complete remission with incomplete hematologic recovery (CRi) rates
Endpoint domain: Mortality/survival
Primary endpoint: Negative measurable residual disease (MRD) rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Safety and toxicity outcomes
Endpoint domain: Adverse events/effects
Primary endpoint: AUC(0-504) of pembrolizumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oral health behavior
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Optimal Biological Dose (OBD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of COVID-19 symptoms after 1 week of treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of COVID-19 symptoms after 2 weeks of treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of significant increases in serum antibody to CoV S protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Frequency and severity of solicited injection site and systemic signs and symptoms
Endpoint domain: Adverse events/effects
Primary endpoint: Contact Lens Dry Eye Questionnaire (CLDEQ-8) Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Effect on NAFLD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Change in TMJ dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes of monofilament force
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to care
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Fugl-Meyer Assessment scale for Upper Extremity (FMAUE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain score T20 with the Face Legs Activity Cry Consolability scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain score T20 with the Visual Analog Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of postoperative CSF leakage
Endpoint domain: Adverse events/effects
Primary endpoint: Major, life threatening bleeding due to profuse bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: Major, life threatening bleeding due to intracranial haemorrhage
Endpoint domain: Adverse events/effects
Primary endpoint: Minor bleeding: Haemoglobin reduction > 10g/l during the treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Frequency of acute vaso-occlusive episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Broad jump distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Unilateral triple jump length
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Locoregional tumour control
Endpoint domain: Mortality/survival
Primary endpoint: Level of Post-operative pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Extension Strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cholesterol and fasting blood glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Time-weighted SaO2/FiO2 ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Accuracy of Temperature Measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Number of Musculoskeletal Injuries
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Core Endurance Performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in coagulation activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Decision-making preferences
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Family cohesion
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Coping behaviors
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Weight change (kg) for STEP versus usual care
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Weight change (kg) for SELF versus usual care
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of Total Ezetimibe, Rosuvastatin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUCt of Total Ezetimibe, Rosuvastatin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Snaith-Hamilton Pleasure Scale (SHAPS) Total Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Hallucinations + Delusions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percentage of Participants With Vaccine-related Serious AEs (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With ≥4-fold Rise From Baseline in Serotype-specific OPAs (Unique to V116)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Displacement of miniscrews
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: NYHA Functional Class
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Children's pain self-efficacy
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Parental management strategies of child's pain
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Donor Site Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with ureteral stent encrustation longer than 4mm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Maximum plasma concentration observed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration-time curve over the 24-hour dosing interval
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time of Progression-free survival (PFS)
Endpoint domain: Mortality/survival
Primary endpoint: Time of Time to progression (TTP)
Endpoint domain: Mortality/survival
Primary endpoint: Change in pain evoked
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to turn off the alarm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Burden of care staff
Endpoint domain: Resource use
Endpoint subdomain: Societal/carer burden
Primary endpoint: HbA1c compliance rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Compliance rate of total cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Compliance rate of BMI (Body Mass Index)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Fear of Pain
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in internal jugular vein blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Pulmonary system change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Cardiac system change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Immunologic system change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Frequency of successful site submissions
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Characterisation of HBV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Solicited AEs over 7 days post-vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Unsolicited AEs and MAAEs over 28 days post-vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: HAI antibody titers specific for the HA receptor binding domains of vaccine homologous A and B influenza strains Expressed as GMT
Endpoint domain: Physiological/clinical
Primary endpoint: Real-time esophageal barium meal examination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: High-resolution esophageal manometry (HREM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Rate of symptomatic intracranial hemorrhage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percentage of responders of dysmenorrhea at week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Percentage of responders of Non-Menstrual Pelvic Pain at week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Time to first occurrence of nonfatal myocardial infarction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time to first occurrence of nonfatal stroke
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: State and Trait Anxiety Inventory (STAI-score)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Heart rate variability (Low Frequency and High Frequency)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of participants who report side-effects related to gastrointestinal (GI) distress
Endpoint domain: Adverse events/effects
Primary endpoint: Normalization of biochemical markers of disease (lactate)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Normalization of biochemical markers of disease (pyruvate)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Normalization of biochemical markers of disease (β-hydroxybutyrate level)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Normalization of biochemical markers of disease (Alanine/Leucine ratio)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Proportion of subjects with serum uric acid levels <360 μmol/L
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of patients non-responsive to medical therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disease impact measured by RAID questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Difference in excess gestational weight gain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Differences in maternal metabolic health post-partum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of participants with less than 1 episode of Antibody-mediated rejection (AMR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of participants with no presence of Donor-specific antibody (DSA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of participants with reduction of DSA titer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Area under the concentration-time curve from time 0 to the last quantifiable time point (AUC[0-T])
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the concentration-time curve from time 0 to 72 hours (AUC[0-72])
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the concentration-time curve from time 0 to infinite time (AUC[0-INF])
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of subjects with esophageal eosinophilia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Lower Extremity Functional Scale (LEFS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of Neuroma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Resolution of Cluster Headache attacks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time-weighted Change From Baseline in Viral Shedding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Self Concept Clarity
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Reflective Functioning
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Successful alignment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: frequency of severe adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: accuracy of fit (adaptation)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: retention
Endpoint domain: Life impact
Endpoint subdomain: null
Primary endpoint: Impact on socio-economic lives
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: working time used for medication management
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Maternal iodine retention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: CNS Objective response rate (CNS-ORR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Incidence of Stimulation-Related Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in Visual Analogue Scale (VAS) score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Urine D/R
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Body Appreciation Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Care Dependency Scale
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Psychosocial Adjustment to Illness-Self-Report Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Objective Response - Number of Participants With Objective Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Experiencing dose-limiting toxicities (DLTs)
Endpoint domain: Adverse events/effects
Primary endpoint: sensitivity of canine detection for prostate cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: specificity of canine detection for prostate cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Kappa concordance coefficient
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in ocular axial length
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Adjective Rating Scale of Withdrawal (ARSW)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the California Verbal Learning Test (CVLT)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in the Brief Visuo-spatial Memory Test (BVMT)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in the Symbol Digit Modalities Test (SDMT)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Nociception Level Index (NoL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tics severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful cannulation of target vessels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Degree of myocardial cell injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes